2008
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Sanacora G, Zarate CA, Krystal JH, Manji HK. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nature Reviews Drug Discovery 2008, 7: 426-437. PMID: 18425072, PMCID: PMC2715836, DOI: 10.1038/nrd2462.Peer-Reviewed Original ResearchConceptsGlutamatergic systemMood disordersAntidepressant effectsNMDA antagonistsDouble-blind placebo-controlled crossover studyTreatment-resistant major depressive disorderPlacebo-controlled crossover studyGlutamate release inhibitorSignificant antidepressant effectNMDA receptor expressionRecurrent mental illnessSingle intravenous doseMajor depressive disorderPotential novel therapeuticsGlutamatergic abnormalitiesCrossover studyGlutamate releaseIntravenous doseMood stabilizersDepressive disorderReceptor expressionReceptor modulatorsEvidence of alterationsCerebrospinal fluidAMPA potentiators
2002
Impact of intravenous nicotine on BOLD signal response to photic stimulation
Jacobsen LK, Gore JC, Skudlarski P, Lacadie CM, Jatlow P, Krystal JH. Impact of intravenous nicotine on BOLD signal response to photic stimulation. Magnetic Resonance Imaging 2002, 20: 141-145. PMID: 12034334, DOI: 10.1016/s0730-725x(02)00494-0.Peer-Reviewed Original ResearchConceptsBOLD signal responseFunctional magnetic resonance imagingPhotic stimulationIntravenous infusionNeuronal activitySuccessive intravenous infusionsBlood oxygen level-dependent (BOLD) signalEffects of nicotineLevel-dependent signalMagnetic resonance imagingHealthy smokersVascular effectsTobacco smokingBrain effectsNicotine receptorsIntravenous nicotineEvidence of alterationsOccipital cortexVisual cortexResonance imagingNicotineBOLD signalStimulationInfusionCortex